Thorac Cardiovasc Surg 2016; 64(06): 475-482
DOI: 10.1055/s-0035-1565001
Original Cardiovascular
Georg Thieme Verlag KG Stuttgart · New York

Predictive Value of EuroSCORE II in Patients Undergoing Left Ventricular Assist Device Therapy

Ares K. Menon*
1  Thoracic and Cardiovascular Surgery, University Hospital RWTH Aachen, Aachen, Germany
,
Mare Mechelinck*
1  Thoracic and Cardiovascular Surgery, University Hospital RWTH Aachen, Aachen, Germany
,
Jan Unterkofler
1  Thoracic and Cardiovascular Surgery, University Hospital RWTH Aachen, Aachen, Germany
,
Andreas Goetzenich
1  Thoracic and Cardiovascular Surgery, University Hospital RWTH Aachen, Aachen, Germany
,
Rüdiger Autschbach
1  Thoracic and Cardiovascular Surgery, University Hospital RWTH Aachen, Aachen, Germany
,
Lachmandath Tewarie
1  Thoracic and Cardiovascular Surgery, University Hospital RWTH Aachen, Aachen, Germany
,
Ajay Moza
1  Thoracic and Cardiovascular Surgery, University Hospital RWTH Aachen, Aachen, Germany
› Author Affiliations
Further Information

Publication History

30 March 2015

10 September 2015

Publication Date:
26 October 2015 (online)

Abstract

Background Left ventricular assist devices (LVADs) are nowadays a widespread option for the effective treatment of heart failure. We hypothesized that the European System for Cardiac Operative Risk Evaluation II (EuroSCORE II) might be a superior tool in clinical decision making compared with other established score systems.

Methods In this retrospective, single-center analysis, between 2008 and 2014, 40 consecutive patients were followed for up to 36 months after LVAD (Thoratec HeartMate II) implantation. Postoperative survival was correlated to the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) levels, Destination Therapy Risk Score (DTRS), HeartMate II Risk Score (HMRS), and EuroSCORE II.

Results Overall, a positive outcome (survival, transplantation, or weaning) was reached in 87.5% (30 days), 70% (1 year), and 60% (2 and 3 years) of cases. Patients were categorized as high, medium, and low risk by use of the different scores. Within the created subgroups, the following 1-year positive outcomes were achieved—INTERMACS: high risk 58% versus low risk 68%; EuroSCORE II: high risk 17% versus low risk 89%; DTRS: high risk 44% versus low risk 75%; and HMRS: high risk 60% versus low risk 100%. After 1 year, the EuroSCORE II classification's area under the receiver operating characteristic curve (AUC) was superior (AUC = 0.78) and Fisher exact test revealed a significant predictive value for this classification (p = 0.0037) but not for INTERMACS levels, DTRS, or HMRS classifications.

Conclusion These results support the assumption that EuroSCORE II risk classification may be useful to predict survival in LVAD patients. In our observation, it proved to be superior to INTERMACS, DTRS, and HMRS after 1 year.

Note

A first analysis of this study was presented at the DGTHG 2013, Freiburg, Germany, in a short oral communication.


* Both the authors contributed equally to this work.